Is Johnson&Johnson (JNJ) stock a buy or sell?
Johnson & Johnson has received a consensus rating of Buy. The company's average rating score is 2.75, and is based on 6 buy ratings, 2 hold ratings, and no sell ratings. According to analysts' consensus price target of $189.75, Johnson & Johnson has a forecasted upside of 15.5% from its current price of $164.34.
Is Johnson&Johnson stock making a comeback in January?
The Centers for Disease Control and Prevention recently said it prefers messenger RNA-based Covid vaccines over Johnson & Johnson 's ( JNJ) — but JNJ stock was making a comeback in early January. This video file cannot be played. (Error Code: 102630)
What are Wall Street analysts'price targets for Johnson&Johnson's stock?
12 Wall Street analysts have issued 1-year price objectives for Johnson & Johnson's shares. Their predictions range from $140.00 to $169.00. On average, they anticipate Johnson & Johnson's stock price to reach $152.10 in the next twelve months.
Is JNJ stock flirting with its buy point?
For the year, JNJ stock analysts call for adjusted profit of $9.82 per share on $94.45 billion in sales, up a respective 22% and 14%. JNJ stock is forming a cup-with-handle base with a buy point at 173.61, according to MarketSmith.com. The stock is now flirting with its buy point.
See more
Why is JNJ stock dropping?
JNJ Stock: Earnings Beat, But Sales Miss Sales of a key immunology drug, Remicade, toppled as patients began switching to biosimilar rivals, which tend to cost less. Meanwhile, revenue from cancer treatment Zytiga and all of the firm's heart-disease drugs declined. The Covid vaccine brought in $457 million in sales.
Is JNJ a good stock to Buy now?
Healthcare juggernaut Johnson & Johnson (JNJ 1.13%) has remained a favorite of dividend-focused investors. Its consistently outstanding performance every quarter, despite market volatility and macro-economic uncertainties, shows how well it handles its business.
Is JNJ a Buy Sell or Hold?
I rate Johnson & Johnson's (NYSE:JNJ) shares as a Buy.
Will JNJ stock go up?
Johnson & Johnson (NYSE:JNJ) The 17 analysts offering 12-month price forecasts for Johnson & Johnson have a median target of 187.00, with a high estimate of 215.00 and a low estimate of 173.00. The median estimate represents a +4.11% increase from the last price of 179.61.
Is Johnson and Johnson going out of business?
J&J itself isn't bankrupt—instead, it has split off a new unit essentially designed to go broke paying legal liabilities. It's part of a maneuver to deal with about 38,000 lawsuits, mostly filed by women who claim one of the company's oldest products, baby powder, causes ovarian cancer.
Is Johnson and Johnson a safe stock?
JNJ's strong financial fundamentals and its market position make it a highly secure option, with its diversified segments that result in a minimized risk exposure for the company.
Is JNJ overvalued?
On a relative basis, the company is fairly valued and on an absolute basis overvalued....About JNJ.SymbolLast Price% ChgJNJPost177.51 176.800.29% -0.40%Oct 26, 2021
What is the target price for Johnson & Johnson?
Stock Price TargetsHigh$215.00Median$187.00Low$173.00Average$188.47Current Price$177.51
Is Johnson and Johnson a good company?
Johnson & Johnson Named to Glassdoor's 2018 List of Best Places to Work Johnson & Johnson Named to Glassdoor's 2018 List of Best Places to Work. The company nabbed a top spot on the annual list—based entirely on positive reviews from its own employees.
Why should I invest in JNJ?
JNJ boasts an average earnings surprise of 7.8%. With strong earnings growth, a good Zacks Rank, and top-tier Momentum and VGM Style Scores, investors should think about adding JNJ to their portfolios.
How many times has Johnson and Johnson stock split?
Johnson and Johnson (JNJ) has 6 splits in our Johnson and Johnson stock split history database. The first split for JNJ took place on May 18, 1970. This was a 3 for 1 split, meaning for each share of JNJ owned pre-split, the shareholder now owned 3 shares.
Is PG a buy or sell?
Today PG ranks #2947 as buy candidate.
What happened
So what
Shares of Johnson & Johnson (NYSE: JNJ) are down more than 2% as of 3:25 p.m. EDT Thursday as potential regulation for prescription drug prices becomes clearer.
Now what
Today, the U.S. Department of Health and Human Services released the Biden administration's plan to drive down costs. It supports allowing the federal government to negotiate drug prices in its Medicare program. That's the federal insurance program for people aged 65 and older. Medicare also includes younger people with disabilities.
The Motley Fool
Don't expect legislation soon. Politicians are still divided -- even Democrats, who largely support the goals of the proposal. For its part, a drug manufacturing trade group pointed to the insurance industry as missing from the list of targets for change.
What are Johnson and Johnson products?
Founded in 1993 in Alexandria, VA., by brothers David and Tom Gardner, The Motley Fool is a multimedia financial-services company dedicated to building the world's greatest investment community.
Where is Johnson and Johnson located?
Johnson & Johnson researches and develops, manufactures, and sells a range of products in the health care field worldwide. It operates through three segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands ; ibuprofen products under the MOTRIN IB brand; smoking cessation products under the NICORETTE brand; and acid reflux products under the PEPCID brand. This segment also provides women's health products, such as sanitary pads and tampons under the STAYFREE, CAREFREE, and o.b. brands; wound care products comprising adhesive bandages under the BAND-AID brand; and first aid products under the NEOSPORIN brand. The Pharmaceutical segment offers products in various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, and cardiovascular and metabolic diseases. The Medical Devices segment provides electrophysiology products to treat cardiovascular diseases and neurovascular care products to treat hemorrhagic and ischemic stroke; orthopaedics products in support of hips, knees, trauma, spine, sports, and other; advanced and general surgery solutions that focus on breast aesthetics, ear, nose, and throat procedures; and disposable contact lenses and ophthalmic products related to cataract and laser refractive surgery under the ACUVUE brand. The company markets its products to general public, and retail outlets and distributors, as well as distributes directly to wholesalers, hospitals, and health care professionals for prescription use. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.
9 cybersecurity stocks to watch amid Russia attacking Ukraine: analyst
Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey. Read More.
Ukraine-Russia crisis won't stop Fed from jacking up interest rates: Goldman Sachs
Wall Street is keyed in on cybersecurity stocks amid Russia's invasion of Ukraine.
The company's vaccine has a lower efficacy rate than others
Goldman Sachs says the Federal Reserve won't be budged on its rate hiking ambitions by the developing Ukraine-Russia crisis.
What happened
Eric has been writing about stocks and finance since the mid-1990s, when he lived in Prague, Czech Republic. Over the course of a varied career, he has also been a radio newscaster, an investment banker, and a bass player in a selection of rock and roll bands. A native New Yorker, he currently lives in Los Angeles.
So what
Johnson & Johnson ( NYSE:JNJ) closed 3.6% lower on Friday. A downward move is exactly the opposite of what you'd expect to happen when a coronavirus vaccine developer announces positive clinical trial results, as the company did that morning.
Now what
Data indicated that Johnson & Johnson's candidate met all of the primary and key secondary endpoints in its phase 3 clinical trial. In the sprawling global study, the vaccine's overall efficacy was 66% in blocking moderate to severe COVID-19. It was 85% effective in preventing severe forms of the disease.
How much did J&J pay for the opioid crisis?
An inoculation efficacy rate of 66% is not as good as that of the competition. The Moderna and Pfizer/BioNTech vaccines both had significantly higher rates (94.1% and 95%, respectively). Still, 66% is considered to be a strong result. Plus, Johnson & Johnson's testing involved more contagious variants of the coronavirus.
How much did Johnson and Johnson pay for the opioids?
J&J will pay $5 billion to settle lawsuits claiming the company had a part in the nation's opioid epidemic. Drug distributors McKesson, AmerisourceBergen and Cardinal Health will pay a combined $21 billion. According to reports, some 40 states could sign onto the deal.
Why is J&J paused?
More bullishly, Johnson & Johnson nabbed a $5 billion deal to settle thousands of lawsuits related to its production of opioids. Related to that, drug distributors McKesson ( MCK ), AmerisourceBergen ( ABC) and Cardinal Health ( CAH) will pay a combined $21 billion.
How much did J&J settle with Ohio?
That followed regulators' decision earlier this year to temporarily pause use of the J&J injection following separate reports of blood clots in women.
Is Johnson and Johnson effective in South Africa?
J&J also settled with two Ohio counties for $10 million. In addition, Johnson & Johnson will pay $5 million in legal fees and make $5.4 million in charitable giving, for a total payout of $20.4 million.
Do J&J need a second shot?
In clinical testing, it was 66% effective against Covid, and 72% effective in the U.S. Promisingly, the vaccine was 57% effective in South Africa. J&J is now contending with the delta variant, which was first identified in India.
Is Ashtyn Evans bullish on Johnson and Johnson?
The authors suggested J&J vaccine recipients would need to receive a second shot of one of the messenger RNA vaccin es from Pfizer ( PFE) or Moderna ( MRNA ). Also this month, the FDA added a warning to the label for J&J's shot regarding the potential for Guillain-Barre syndrome.
Does Johnson & Johnson have asbestos?
Edward Jones analyst Ashtyn Evans is bullish on Johnson & Johnson's chances. "The company's earnings growth has accelerated, driven by newly launched drugs and a decreasing impact from patent losses," she said in a post-earnings report to clients.
Is the DOJ a criminal investigation?
And in December, Reuters reported that Johnson & Johnson knew for decades that its talcum powder products contained asbestos.
Ownership
- Johnson & Johnson trades on the New York Stock Exchange (NYSE) under the ticker symbol \"JNJ.\" Johnson & Johnson's stock is owned by a variety of of institutional and retail investors. Top institutional investors include BlackRock Inc. (7.04%), Northern Trust Corp (1.30%), Boston Partners (0.46%), Sumitomo Mitsui Trust Holdings Inc. (0.41%), Swiss National Bank (0.37%) an…
Release
- Johnson & Johnson is scheduled to release their next quarterly earnings announcement on Tuesday, July 16th 2019. View Earnings Estimates for Johnson & Johnson.
Sales
- Johnson & Johnson issued an update on its FY19 earnings guidance on Tuesday, April, 16th. The company provided earnings per share (EPS) guidance of $8.53-8.63 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $8.59. The company issued revenue guidance of $80.4-81.2 billion, compared to the consensus revenue es...
Risks
- 11 brokerages have issued 1-year price targets for Johnson & Johnson's shares. Their forecasts range from $129.00 to $157.00. On average, they expect Johnson & Johnson's share price to reach $146.00 in the next year. This suggests a possible upside of 6.4% from the stock's current price. View Analyst Price Targets for Johnson & Johnson.
Ratings
- 11 Wall Street analysts have issued \"buy,\" \"hold,\" and \"sell\" ratings for Johnson & Johnson in the last year. There are currently 5 hold ratings and 6 buy ratings for the stock, resulting in a consensus recommendation of \"Buy.\" View Analyst Ratings for Johnson & Johnson.
Reviews
- News headlines about JNJ stock have been trending positive recently, InfoTrie Sentiment reports. The research firm rates the sentiment of press coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Johnson & Johnson ea…
Business
- Johnson & Johnson has a market capitalization of $368.09 billion and generates $81.58 billion in revenue each year. The company earns $15.30 billion in net income (profit) each year or $8.18 on an earnings per share basis. Johnson & Johnson employs 135,100 workers across the globe.